RxDoctor Payments Data

Zain Jabri

Hospitalist · Duarte, CANPI 1891159620

Payments from drug & device makers

$562in general payments, 2019–2025

Across 13 payments — averaging $43.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$285
  • Boehringer Ingelheim$125
  • GSK$31
  • Otsuka America Pharmaceutical, Inc.$28
  • Dexcom, Inc.$22
  • Astellas Pharma US Inc$21
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$562100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$562 in reported general payments places this provider in the 80th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Medicare billing

Part B allowed, 2024
$44,012
Medicare patients
180
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$97,450
JardianceEmpagliflozin61$47,021
FarxigaDapagliflozin Propanediol70$44,586
RybelsusSemaglutide49$43,472
JanumetSitagliptin Phos/Metformin Hcl51$29,542
EliquisApixaban35$25,690
EntrestoSacubitril/Valsartan22$21,362
TrulicityDulaglutide20$18,474
JanuviaSitagliptin Phosphate25$16,318
XareltoRivaroxaban13$15,321
MounjaroTirzepatide13$14,073
LinzessLinaclotide20$10,009
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,242
TradjentaLinagliptin11$8,233
JentaduetoLinagliptin/Metformin Hcl13$6,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$125$61,72285 claims
AstraZenecaFarxiga$14$44,58670 claims
Lilly USA, LLCTrulicity, Mounjaro$19$32,54733 claims
GSKTrelegy Ellipta$31$8,24213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,469 hospitalist providers in California.

Other hospitalist in Duarte

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →